Latest News
Sanofi and Regeneron's Dupixent gains Japan approval as first targeted therapy for bullous pemphigoid
24 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) said on Tuesday that they have received marketing and manufacturing authorisation in Japa...
Pharming secures Japan approval for Joenja in rare immune disorder treatment
24 March 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has approved Joenja (leniolisib) for the treatment of activated phosp...
Abbott completes Exact Sciences acquisition
24 March 2026 - Global healthcare company Abbott (NYSE:ABT) confirmed on Monday that it has completed the acquisition of molecular diagnostics company Exact Sciences.According to Abbott, this acquisition establishes its position as a leader in fast-g...
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
24 March 2026 - Rare disease pharmacy solutions provider Orsini announced on Monday that it has been selected by ophthalmic pharmaceuticals and medical technology company Glaukos Corporation (NYSE:GKOS) as its single-source specialty pharmacy partner...
UCB selects PANTHERx Rare to distribute KYGEVVI for TK2d
24 March 2026 - PANTHERx Rare Pharmacy, a specialty pharmacy focused on rare and orphan diseases, announced on Monday that it has been selected by Belgium-based biopharmaceutical company UCB (EBR:UCB) as the exclusive specialty pharmacy for the distr...